Anticoagulation: Drugs, Duration & Monitoring | Apex Hospitals

  • Anticoagulation is a key component of treatment and prevention for conditions in which abnormal blood clots can form within blood vessels. Anticoagulant medicines reduce the blood’s ability to form or extend clots and are commonly used for conditions such as deep vein thrombosis (DVT), pulmonary embolism and certain heart rhythm disorders.

Anticoagulation does not directly dissolve an existing clot. Instead, it helps prevent the clot from becoming larger while the body’s natural processes gradually break it down.

Why Anticoagulation Is Used

  • Anticoagulants may be prescribed for:
  • Deep vein thrombosis
  • Pulmonary embolism
  • Atrial fibrillation
  • Prevention of venous thromboembolism after selected surgeries
  • Certain mechanical heart valves
  • Other conditions associated with increased clotting risk

The choice of treatment depends on the underlying condition, risk of recurrence and the patient’s risk of bleeding.

Common Anticoagulant Medicines

  • Several classes of anticoagulants are available.

Direct Oral Anticoagulants

Direct oral anticoagulants (DOACs) include medicines such as:

  • Apixaban
  • Rivaroxaban
  • Edoxaban
  • Dabigatran

These medicines are widely used for many patients with DVT, pulmonary embolism and atrial fibrillation.

Their dosing depends on the specific medicine, indication, kidney function and other clinical factors.

Warfarin

Warfarin is a vitamin K antagonist that has been used for many years.

Unlike most DOACs, warfarin requires regular blood testing to monitor its anticoagulant effect.

The dose is adjusted according to the international normalised ratio (INR).

Warfarin remains particularly important in certain situations, including many patients with mechanical heart valves.

Heparin

Heparin and low-molecular-weight heparins are commonly used when rapid anticoagulation is required.

They may be administered:

  • During hospital treatment
  • Around certain surgical procedures
  • During pregnancy in selected situations
  • As initial treatment for certain thromboembolic conditions

The specific drug and dose depend on the clinical circumstances.

Choosing the Appropriate Anticoagulant

  • Anticoagulant selection is individualised.

Important factors include:

  • Type of clotting disorder
  • Kidney function
  • Liver function
  • Age
  • Body weight
  • Bleeding risk
  • Pregnancy status
  • Other medications
  • Previous bleeding
  • Presence of cancer
  • Need for surgery or invasive procedures

The treatment that is appropriate for one patient may not be appropriate for another.

Duration of Anticoagulation

  • The duration of treatment depends mainly on why the clot occurred and the patient’s future risk of thrombosis and bleeding.

For some patients, anticoagulation is given for a defined period.

Longer treatment may be considered when there is:

  • Recurrent venous thromboembolism
  • Persistent risk factors
  • Certain thrombophilic conditions
  • Atrial fibrillation requiring stroke prevention
  • Mechanical heart valves

Treatment duration should be reviewed periodically rather than continued indefinitely without reassessment.

Monitoring During Treatment

  • Monitoring requirements vary according to the anticoagulant.

Patients taking warfarin require regular INR testing to maintain the medication within the appropriate therapeutic range.

Patients taking DOACs generally do not require routine INR monitoring, but periodic assessment of:

  • Kidney function
  • Liver function
  • Blood counts
  • Medication interactions

remains important.

Patients receiving heparin may require specific laboratory monitoring depending on the preparation and clinical situation.

Bleeding Risk

  • The major complication of anticoagulation is bleeding.

Minor bleeding may include:

  • Easy bruising
  • Nosebleeds
  • Bleeding from the gums
  • Prolonged bleeding from small cuts

More significant bleeding may present as:

  • Blood in urine
  • Black or bloody stools
  • Vomiting blood
  • Heavy menstrual bleeding
  • Persistent or severe bleeding
  • Sudden severe headache
  • Unexplained weakness or neurological symptoms

Significant bleeding requires urgent medical assessment.

Drug and Food Interactions

  • Some anticoagulants interact with other medicines.

Examples include interactions with:

  • Certain antibiotics
  • Antifungal medicines
  • Anti-inflammatory medicines
  • Antiplatelet drugs
  • Some seizure medicines
  • Herbal supplements

Warfarin also interacts with vitamin K intake and numerous medications.

Patients should inform their healthcare team about all prescribed medicines, over-the-counter drugs and supplements before starting or changing anticoagulation.

Anticoagulation Around Surgery

  • Anticoagulants may need to be temporarily interrupted before certain operations or invasive procedures.

The timing depends on:

  • The anticoagulant being used
  • Kidney function
  • Bleeding risk of the procedure
  • Risk of thrombosis if treatment is interrupted

Some high-risk patients may require a carefully planned alternative anticoagulation strategy during the interruption period.

Anticoagulants should not be stopped independently because sudden interruption can increase the risk of thrombosis in certain conditions.

Anticoagulation in DVT

  • For deep vein thrombosis, anticoagulants prevent the clot from extending and reduce the risk of pulmonary embolism.
  • Treatment commonly begins with a DOAC or another appropriate anticoagulant.
  • The duration depends on whether the DVT was associated with a temporary trigger, persistent risk factor or previous thrombotic events.
  • Compression therapy and early mobilisation may also form part of the overall management plan in selected patients.

Anticoagulation in Pulmonary Embolism

  • Pulmonary embolism occurs when a clot travels to the lungs.
  • Anticoagulation is the primary treatment for most clinically stable patients.

Patients with severe pulmonary embolism and circulatory instability may require more intensive treatment, including thrombolysis or catheter-based or surgical intervention in selected cases.

Anticoagulation in Atrial Fibrillation

  • In atrial fibrillation, abnormal heart rhythm can allow blood to stagnate within the heart and form a clot.
  • A clot can subsequently travel to the brain and cause an ischaemic stroke.
  • Anticoagulation is prescribed when the patient’s calculated stroke risk and clinical circumstances indicate that the benefits outweigh the bleeding risk.

Special Situations

  • Certain patients require additional consideration before anticoagulation is prescribed.

These include patients with:

  • Pregnancy
  • Active cancer
  • Severe kidney disease
  • Liver disease
  • Recent surgery
  • Previous major bleeding
  • Mechanical heart valves
  • Very low platelet counts

The anticoagulant and dose must be selected according to the individual clinical situation.

Conclusion

Anticoagulation is an important treatment for preventing clot progression and recurrent thromboembolic events. The choice of drug and duration depends on the underlying condition, kidney and liver function, bleeding risk and other individual factors. Although DOACs often require less laboratory monitoring than warfarin, regular clinical review remains important.

  • At Apex Hospitals, anticoagulation can be selected and monitored according to the patient’s diagnosis, clotting risk, bleeding risk and other medical conditions.

Book An Appointment

Book Appointment